The Congress on Cellular and Humoral Immunotherapy in Autoimmunity (CHIA 2025)
Hybrid Event
Sep 18 - 20, 2025
Paris, Ile-de-France, FR
10.5 ECMEC 
OVERVIEW
The Congress on Cellular and Humoral Immunotherapy in Autoimmunity (CHIA 2025) is organized by CME Congresses Ltd and will be held from Sep 18 - 20, 2025 at The Star Meridian, Paris, Ile-de-France, France.
Description:
The field of immunotherapy is advancing rapidly, and this conference provides a vital platform for exploring the latest breakthroughs and emerging trends in both cellular and humoral immunotherapies, particularly in the context of autoimmune diseases. This year’s theme emphasizes bridging the gap between treatments for haematological malignancies and autoimmune disorders, highlighting the significant overlap and unique challenges shared by these fields.
Throughout the congress, we will have the privilege of hearing from leading experts, researchers, and clinicians who are at the forefront of developing new therapies and treatment strategies. With a combination of cutting-edge research presentations and engaging interactions, we aim to foster meaningful discussions about the most recent innovations, challenges, and breakthroughs in immunotherapy.
We are proud to present a comprehensive program featuring renowned speakers, each sharing their expertise on topics ranging from immune system modulation to the clinical applications of CAR T-cell therapy, T cell engagers, and B-cell lineage targeting in autoimmunity. These discussions will deepen our understanding and broaden the potential for more effective, personalized treatments.
Preliminary Program:
| Day 1 – Thursday, September 18, 2025 | |
|---|---|
| 14:00-15:45 | Session 1: Introduction to CAR-T- and T-cell engagers in autoimmunity |
| 14:00-14:15 | Welcome Dror Mevorach, Israel, Mohamad Mohty, France, Arnon Nagler, Israel |
| 14:15-15:00 | Plenary lecture: SLE pathogenesis and CAR T regulatory cell treatment George Tsokos, USA |
| 15:00-15:45 | From SLE to myasthenia gravis: What are the current bispecific/tri-specific T-cell engagers and CAR T in development for autoimmunity? Dror Mevorach, Israel |
| 16:00-16:30 | Coffee break |
| 16:30-17:15 | Session 2: Resetting autoimmunity treatment |
| 16:30-17:00 | Rheumatoid arthritis: From inverse pyramid through biologics to CAR T and BiTE. Historical perspective Josef Smolen, Austria |
| 17:00-17:30 | Resetting autoimmunity in immune-mediated inflammatory diseases Gerhard Krönke, Germany |
| 17:30-18:15 | Session 3: Oral Abstract Presentations |
| 18:45 | WELCOME RECEPTION |
| CAR T- BCMA in Autoimmune Diseases Day 2 – Friday, September 19, 2025 | |
|---|---|
| 09:00-10:30 | Session 4: From haemato-oncology to rheumatology |
| 09:00-09:30 | CAR T-cells: From hematology to autoimmunity Arnon Nagler, Israel |
| 09:30-10:00 | Current European guidelines for HSCT and CAR T in autoimmune diseases Raffaella Greco, Italy |
| 10:00-10:30 | CAR-T- and T-cell engagers TBA |
| 10:30-11:00 | Coffee break |
| 11:00-13:00 | Session 5: |
| 11:00-11:30 | TBA |
| 11:30-12:00 | CAR T for scleroderma? Could we cure the disease? TBA |
| 12:00-12:30 | CAR T in neurological autoimmunity Aiden Haghikia, Germany |
| 12:30-13:00 | CAR T- BCMA in Autoimmune Diseases |
| 13:00-14:00 | Lunch |
| 14:00-16:00 | Session 6: Miscellaneous cell therapies for autoimmunity |
14:00-14:45 | Plenary lecture: CRISPR-based T-cell editing for allogeneic CAR T Huji Xu, China |
14:45-15:15 | Are cells from patients with autoimmunity suitable for CAR T generation? Limits and perspectives |
15:15-15:45 | NK cell therapy: from oncology to autoimmunity TBA |
15:45-16:15 | Additional cell therapies and their role in autoimmunity (iPSCs, MSC, apoptotic) TBA |
16:15-16:45 | Coffee break |
16:45-18:15 | Session 7: |
16:45-17:15 | Oral presentations |
17:15-18:15 | Poster viewing |
18:15-19:00 | Session 8: |
18:15-19:00 | Debate: Autologous or heterologous CAR T therapy for autoimmunity? TBA |
| 19:30 | FACULTY DINNER |
| Day 3 – Saturday, September 20, 2025 | |
|---|---|
| 09:00-10:30 | Session 9: |
| 09:00-09:30 | T-cell engagers in autoimmune diseases Ricardo Grieshaber-Bouyer, Germany |
| 09:30-10:00 | CAR T safety in autoimmune diseases Melanie Hagen, Germany |
| 10:00-10:30 | Is there a cancer risk in treating patients with CAR T? Remy Dulery, USA |
| 10:30-11:00 | Coffee break |
| 11:00-13:00 | Session 10: |
| 11:00-11:30 | TBA |
| 11:30-12:00 | Commercially conscious development of cell therapies TBA |
| 12:00-12:30 | Autoreactive B-cell depletion by CAR T-cells for ANCA vasculitis Avery Posey, Jr., USA |
| 12:30-13:00 | TBA |
| 13:00-14:00 | Lunch |
| 14:00-16:00 | Session 11: Near future perspectives |
| 14:00-14:30 | CAR T-IL-10 Tang Li, Switzerland |
| 14:30-15:00 | Increasing CAR T efficiency Jamie Frankish, Ireland |
| 15:00-15:30 | Systematic identification of targets improving T-cell therapies Laurie Menger, France |
| 16:00-16:30 | Coffee break |
| 16:30-18:00 | Session 12: |
| 16:30-17:30 | Debate: CAR T or BiTE for autoimmunity? TBA |
| 17:30 | Closing remarks Dror Mevorach, Israel, Mohamad Mohty, France, Arnon Nagler, Israel |
KEY DATES
18 Sep, 2025
Event Start Date
20 Sep, 2025
Event End Date
ACCREDITATION & CREDITS
CME Accreditation
“The Congress on Cellular and Humoral Immunotherapy in Autoimmunity, Paris, France 18/09/2025 – 20/09/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 10.5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”
“Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM.
“Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”
Information regarding the conversion of EACCME®
credits Credit will be converted based on one (1) hour of participation equaling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA.
TARGET AUDIENCE
PhysicianEndocrinologistsScientistsStudentsDermatologistsResidentsNeurologistsNursesGastroenterologistsRheumatologistsImmunologistsSPECIALITIES
RheumatologyImmunotherapiesGastroenterologyNeurologyDermatologyEndocrinologyHaematologyCONFERENCE SUMMARY
The Congress on Cellular and Humoral Immunotherapy in Autoimmunity (CHIA 2025) is set to be a pivotal event for researchers and healthcare professionals. Scheduled for 2025, this hybrid conference will explore cutting-edge advancements in immunotherapy for autoimmune diseases. Attendees can expect insightful talks from leading experts, interactive workshops, and networking opportunities. The event promises to enhance understanding of cellular and humoral responses, offering valuable insights for clinical applications. Don’t miss the chance to engage with the latest research and innovations in immunotherapy at CHIA 2025.
SUGGESTED HOTELS
CONFERENCE VENUE
The Star MeridianCANCELLATION & REFUND POLICY
All cancellations must be faxed, electronically mailed or postmarked. Refund of registration fees will be as follows:
Postmarked up until June 18, 2025- 100% refund (minus € 50 handling fee and bank charges)
Postmarked from June 19, 2025- 50% refund
No refund on cancellations sent after September 1, 2025.
RELATED CONFERENCES & LIVE WEBINARS
Quick Links